Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years

INTRODUCTION: In clinical trials, recombinant factor IX fusion protein (rFIXFc) has demonstrated safety, efficacy and prolonged activity with extended dosing intervals for treatment of haemophilia B. AIM: To assess the real‐world clinical utility of rFIXFc in a variable patient population and routin...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Amy, Chaudhury, Ateefa, Wang, Michael, Escobar, Miguel, Tsao, Elisa, Barnowski, Christopher, Feng, Jing, Jain, Nisha, Quon, Doris V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821220/
https://www.ncbi.nlm.nih.gov/pubmed/33012060
http://dx.doi.org/10.1111/hae.14152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821220/
https://www.ncbi.nlm.nih.gov/pubmed/33012060
http://dx.doi.org/10.1111/hae.14152

Ejemplares similares